AU2009293007B2 - Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma - Google Patents

Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma Download PDF

Info

Publication number
AU2009293007B2
AU2009293007B2 AU2009293007A AU2009293007A AU2009293007B2 AU 2009293007 B2 AU2009293007 B2 AU 2009293007B2 AU 2009293007 A AU2009293007 A AU 2009293007A AU 2009293007 A AU2009293007 A AU 2009293007A AU 2009293007 B2 AU2009293007 B2 AU 2009293007B2
Authority
AU
Australia
Prior art keywords
cspg4
antibody
cells
cell
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009293007A
Other languages
English (en)
Other versions
AU2009293007A1 (en
Inventor
Soldano Ferrone
Xinhui Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of AU2009293007A1 publication Critical patent/AU2009293007A1/en
Application granted granted Critical
Publication of AU2009293007B2 publication Critical patent/AU2009293007B2/en
Priority to AU2015268743A priority Critical patent/AU2015268743B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009293007A 2008-09-19 2009-09-18 Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma Ceased AU2009293007B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015268743A AU2015268743B2 (en) 2008-09-19 2015-12-15 Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9854808P 2008-09-19 2008-09-19
US61/098,548 2008-09-19
PCT/US2009/057578 WO2010033866A2 (en) 2008-09-19 2009-09-18 Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015268743A Division AU2015268743B2 (en) 2008-09-19 2015-12-15 Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma

Publications (2)

Publication Number Publication Date
AU2009293007A1 AU2009293007A1 (en) 2010-03-25
AU2009293007B2 true AU2009293007B2 (en) 2015-10-08

Family

ID=42040172

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2009293007A Ceased AU2009293007B2 (en) 2008-09-19 2009-09-18 Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma
AU2015268743A Ceased AU2015268743B2 (en) 2008-09-19 2015-12-15 Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2015268743A Ceased AU2015268743B2 (en) 2008-09-19 2015-12-15 Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma

Country Status (6)

Country Link
US (3) US8486393B2 (enExample)
EP (1) EP2338055A4 (enExample)
JP (1) JP2012503203A (enExample)
AU (2) AU2009293007B2 (enExample)
CA (1) CA2737758C (enExample)
WO (1) WO2010033866A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2200634B1 (en) 2007-09-21 2015-02-11 The Regents of The University of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
AU2009293007B2 (en) 2008-09-19 2015-10-08 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma
WO2011009090A1 (en) 2009-07-16 2011-01-20 Xoma Technology Ltd. Antibodies to high molecular weight melanoma associated antigen
US20110243993A1 (en) * 2010-03-29 2011-10-06 Broo Kerstin S Method for diagnosing and creating immunogenic tolerance in contact allergy and other epithelial immunotoxicological ailments
JP5451552B2 (ja) * 2010-08-09 2014-03-26 オリンパス株式会社 顕微鏡システム、標本観察方法およびプログラム
WO2014089354A1 (en) 2012-12-07 2014-06-12 The Regents Of The University Of California Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
WO2014194100A1 (en) * 2013-05-29 2014-12-04 The Regents Of The University Of California Anti-cspg4 fusions with interferon for the treatment of malignancy
US9782500B2 (en) 2013-09-24 2017-10-10 Oncoinvent As Monoclonal antibody and derivatives
EP3074025A1 (en) 2013-11-27 2016-10-05 Baylor College Of Medicine Csgp4-specific chimeric antigen receptor for cancer
ES2939760T3 (es) 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
US20160032007A1 (en) * 2014-04-28 2016-02-04 Duke University Human Antibody Fragments Against Chondroitin Sulfate Proteoglycan 4 (CSPG4)
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
WO2016077638A1 (en) * 2014-11-12 2016-05-19 Memorial Sloan Kettering Cancer Center Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
WO2016103205A1 (en) * 2014-12-23 2016-06-30 Universita' Degli Studi Di Parma Pro-apoptotic anti-ng2/cspg4 antibodies and their uses for disease therapy
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016164408A1 (en) * 2015-04-06 2016-10-13 The General Hospital Corporation Anti-cspg4 reagents and methods of treating cancer
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
PL3380620T3 (pl) 2015-11-23 2024-11-12 Novartis Ag Zoptymalizowane lentiwirusowe wektory transferowe i ich zastosowanie
CA3009709A1 (en) 2015-12-30 2017-07-06 Novartis Ag Immune effector cell therapies with enhanced efficacy
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
CN111566124A (zh) 2017-10-25 2020-08-21 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020086758A1 (en) 2018-10-23 2020-04-30 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
US12479817B2 (en) 2019-02-15 2025-11-25 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020222345B2 (en) 2019-02-15 2022-11-17 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP2023506958A (ja) 2019-12-20 2023-02-20 ノバルティス アーゲー 骨髄線維症および骨髄異形成症候群を処置するための、デシタビンまたは抗ｐｄ－１抗体スパルタリズマブを伴うかまたは伴わない抗ｔｉｍ－３抗体ｍｂｇ４５３および抗ｔｇｆ－ベータ抗体ｎｉｓ７９３の組合せ
AU2021260960A1 (en) 2020-04-22 2022-11-24 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
AU2021288224A1 (en) 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
US20240384293A1 (en) 2021-04-27 2024-11-21 Novartis Ag Viral vector production system
US20250313648A1 (en) * 2021-12-07 2025-10-09 Regents Of The University Of Minnesota Binders of Chondroitin Sulfate Proteoglycan (CSPG4) Polypeptides
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
JPWO2024106394A1 (enExample) * 2022-11-14 2024-05-23
AU2024276994A1 (en) 2023-05-24 2025-10-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197328A1 (en) * 2003-01-21 2004-10-07 Young David S. F. Cytotoxicity mediation of cells evidencing surface expression of MCSP
WO2006045750A2 (en) * 2004-10-20 2006-05-04 Friedrich-Alexander- Universität Erlangen- Nürnberg T-cell stimulatory peptides from the melanoma-associated chondroitin sulfate proteoglycan and their use
WO2007109193A2 (en) * 2006-03-16 2007-09-27 Health Research Inc. Inhibition of breast carcinoma stem cell growth and metastasis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE115412T1 (de) 1988-05-17 1994-12-15 Soldano Ferrone Anti-idiotyp-antikörper gegen antimenschliche hochmolekulare, an melanomen assoziierte antigene.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2601858A1 (en) * 2005-03-25 2006-09-28 Glycart Biotechnology Ag Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
AU2009293007B2 (en) * 2008-09-19 2015-10-08 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197328A1 (en) * 2003-01-21 2004-10-07 Young David S. F. Cytotoxicity mediation of cells evidencing surface expression of MCSP
WO2006045750A2 (en) * 2004-10-20 2006-05-04 Friedrich-Alexander- Universität Erlangen- Nürnberg T-cell stimulatory peptides from the melanoma-associated chondroitin sulfate proteoglycan and their use
WO2007109193A2 (en) * 2006-03-16 2007-09-27 Health Research Inc. Inhibition of breast carcinoma stem cell growth and metastasis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG, X. et al., 98th Annual Meeting of the American Association for Cancer Research, 2007, Abstract #1321 *

Also Published As

Publication number Publication date
US9096661B2 (en) 2015-08-04
US20110171229A1 (en) 2011-07-14
US8486393B2 (en) 2013-07-16
EP2338055A2 (en) 2011-06-29
US20150290308A1 (en) 2015-10-15
AU2009293007A1 (en) 2010-03-25
US9801928B2 (en) 2017-10-31
WO2010033866A2 (en) 2010-03-25
WO2010033866A3 (en) 2010-05-27
US20140004124A1 (en) 2014-01-02
CA2737758C (en) 2017-10-31
CA2737758A1 (en) 2010-03-25
AU2015268743B2 (en) 2017-07-13
EP2338055A4 (en) 2012-10-31
JP2012503203A (ja) 2012-02-02
AU2015268743A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
AU2009293007B2 (en) Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma
US10640571B2 (en) Human monoclonal antibodies specific for glypican-3 and use thereof
AU2013306076B2 (en) Mesothelin domain-specific monoclonal antibodies and use thereof
JP6170926B2 (ja) 癌胎児抗原関連細胞接着分子（ｃｅａｃａｍ）に対する抗体
KR102017070B1 (ko) 치료 펩티드
KR20170008202A (ko) 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
US8476410B2 (en) Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
KR20160055831A (ko) 엽산 수용체 1의 검출을 위한 항체 및 분석
KR20190003561A (ko) Alk7 결합 단백질 및 이들의 용도
KR20180042423A (ko) Cd37 의 검출을 위한 항체 및 검정
Durrant et al. A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis
WO2021251460A1 (ja) Ｃａｆを有するがんを処置するための組成物
WO2002018584A2 (en) Xage-1, a gene expressed in multiple cancers, and uses thereof
AU2009305715B8 (en) Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
HK1228931B (en) Human monoclonal antibodies specific for glypican-3 and use thereof
HK1228931A1 (en) Human monoclonal antibodies specific for glypican-3 and use thereof
HK1219965B (en) Human monoclonal antibodies specific for glypican-3 and use thereof
HK1213000B (en) Mesothelin antibodies and methods for eliciting potent antitumor activity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired